Epigenetic Inhibitors

Epigenetics is defined as the stable and heritable alternations in gene expression without changing the DNA nucleotide sequence. The initiation and progression of cancer result from not only genetic mutation, but also aberrant epigenetic regulation, such as DNA methylation and histones acetylation. Although genetic alternations cannot be reversed, epigenetic modification is a dynamic and reversible process.

Over the past few decades, much progress has been made in the research of epigenetic medications and a variety of drugs have been developed targeting epigenetic regulatory proteins, which are capable of restoring malignant cancer cells to the normal state. The epigenetic drugs currently approved for cancer treatment mainly target at DNA methylation and histones acetylation. In addition, there are a great many epigenetic drugs in clinical trials for cancer therapy. antibodies-online.com is able to support your research on epigenetic drugs.

antibodies-online.com offers inhibitors of important epigentic targets such as inhibitors of DNA methyltransferases, histone deacetylases, histone methyltransferases, lysine specific demethylases, and BET (bromodomain and extra-terminal domain) family proteins. Discover our selection down below or browse all available inhibitors.

Acetyltransferase Inhibitors

Bromodomain Inhibitors

DNA Inhibitors

DNA Methyltransferase Inhibitors

Kinase Inhibitors

Protein Deacetylase Inhibitors

Protein Demethylase Inhibitors

Protein Methyltransferase Inhibitors